The structure of RNA polymerase II in a complex with the inhibitor ␣-amanitin has been determined by x-ray crystallography. The structure of the complex indicates the likely basis of inhibition and gives unexpected insight into the transcription mechanism.
and B-factor refinement of the pol II model and minor adjustments to the model, an ␣-amanitin model was placed. The ␣-amanitin model was generated from 6Ј-O-methyl-␣-amanitin (S)-sulfoxide methanol solvate monohydrate as obtained from the Cambridge Structure Database [accession code 3384082 (10) ]. To conform to the known composition and stereochemistry of ␣-amanitin, the 6Ј-O-methyl group was removed from the 6Ј-O-methyltryptophan residue (␣-amanitin position 4) and the stereochemistry of the sulfoxide was modified to R. Topology and refinement parameter files for use in CNS for the ␣-amanitin structure were generated by using HIC-UP (11) . Rigid body refinement was performed on the ␣-amanitin alone, followed by positional and B-factor refinement of the entire pol II-␣- Munich, Germany. † To whom reprint requests should be addressed. E-mail: kornberg@stanford.edu.
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amanitin complex and further minor adjustment of the model, giving a final free-R factor of 28% ( Table 2 ). The refined A-weighted 2F obs Ϫ F calc map (Fig. 1B) clearly shows density for the main chain atoms. Some of the side chains, however, such as that of the 4,5-dihydroxyisoleucine residue, are only partially visible (ordered) in the map. The stereo chemistry of the 4,5-dihydroxyisoleucine ␥ hydroxyl is important in amanitin inhibition, suggestive of a role in hydrogen bonding (12) . Poor ordering in our cocrystal indicates that at least in yeast, the proposed hydrogen bond is not formed. This may partially explain the lesser sensitivity of Saccharomyces cerevisiae to ␣-amanitin compared with other eukaryotes (4).
Results and Discussion
The ␣-amanitin binding site is beneath a ''bridge helix'' extending across the cleft between the two largest pol II subunits, Rpb1 and Rpb2, in a ''funnel''-shaped cavity in the pol II structure (Fig. 2 A and B) . Most pol II mutations affecting ␣-amanitin inhibition map to this site ( Table 3) , showing that it is functionally relevant and not an artifact of crystallization (13) (14) (15) . Pol II residues interacting with ␣-amanitin are located almost entirely in the bridge helix (in the previously defined ''cleft'' region of Rpb1) and in an adjacent part of Rpb1 on the Rpb2-side of the cleft [in the previously defined funnel region of Rpb1 (Fig. 3 A and B ; Table 3) ]. There is a strong hydrogen bond between hydroxyproline 2 of ␣-amanitin and bridge helix residue Glu-A822. There is an indirect interaction involving the backbone carbonyl group of 4,5-dihydroxyisoleucine 3 of ␣-amanitin, hydrogen-bonded to residue Gln-A768, which is, in turn, hydrogen-bonded to bridge helix residue His-A816. Finally, there are several hydrogen bonds between ␣-amanitin and the region of Rpb1 adjacent to the bridge helix. Binding of ␣-amanitin therefore buttresses the bridge helix, constraining its position with respect to the Rpb2-side of the cleft.
This mode of ␣-amanitin interaction can account for the biochemistry of inhibition. There is little if any inf luence of ␣-amanitin binding on the affinity of pol II for nucleoside triphosphates (5, 16) . Moreover, after the addition of ␣-amanitin to a transcribing pol II complex, a phosphodiester bond can 
⌬ surface area (Å 2 ) is the change in solvent-exposed surface as calculated with program AREAIMOL, using a standard probe radius of 1.4 Å. Potential hydrogen bonds with a donor-acceptor distance below 3.3 Å were included. Residues that are different between yeast and human are in bold. Mutations are changes in Rpb1 in eukaryotes that are known to affect ␣-amanitin inhibition. ␣-Amanitin also seems to make a contact with part of the disordered loop between A1081 and A1092. Unfortunately, only density for ϳ1 amino acid appears, preventing placement of this loop or even reliable determination of which amino acid in the disordered loop is responsible for this interaction.
still be formed (17, 18) . The rate of translocation of pol II on DNA is, however, reduced from several thousand to only a few nucleotides per minute (5, 6) . These findings are consistent with binding of ␣-amanitin too far from the active site to interfere with nucleoside triphosphate entry or RNA synthesis (or its reversal) (Fig. 2 A; ref. 5 ). They may be explained by a constraint on bridge helix movement. It was previously suggested that such movement is coupled to DNA translocation. The suggestion was based on two observations. First, in the structure of a pol II-transcribing complex, bridge helix residues directly contact the DNA base paired with the first base in the RNA strand. Second, although the sequence of the bridge helix is well conserved, the conformation is different in a bacterial RNA polymerase structure, with bridge helix residues in position to contact the second base in the DNA strand (1, 2, 19) . Movement of bridge helix residue Glu-A822 by as little as 1 Å would extend the length of the donor-acceptor pair for the hydrogen bond to hydroxyproline 2 of ␣-amanitin beyond 3.3 Å, effectively breaking the bond.
Structural derivatives of ␣-amanitin show the importance of bridge helix interaction for inhibitory activity. The derivative proamanullin, which lacks the hydroxyl group of hydroxyproline 2, involved in hydrogen bonding to bridge helix residue Glu-A822, and which also lacks both hydroxyl groups of 4,5-dihroxyisoleucine 3, is about 20,000-fold less inhibitory than ␣-amanitin. This effect is caused almost entirely by the alteration of hydroxyproline 2, because alteration of 4,5-dihydroxyisoleucine 3 alone, in the derivative amanullin, reduces inhibition only about 4-fold (4, 20) . Other changes in ␣-amanitin structure may affect inhibition indirectly, by diminishing the overall affinity for pol II. For example, shortening the side chain of isoleucine-6 of ␣-amanitin reduces inhibition by about 1,000-fold. This side chain inserts in a hydrophobic pocket of pol II in the cocrystal structure.
Thus three lines of evidence on ␣-amanitin inhibition, coming from biochemical studies of transcription, from structureactivity relationships, and from cocrystal structure determination, converge on a simple picture. Binding of ␣-amanitin to pol II permits nucleotide entry to the active site and RNA synthesis but prevents the translocation of DNA and RNA needed to empty the site for the next round of synthesis. The inhibition of translocation is caused by interaction of ␣-amanitin with the pol II bridge helix, whose movement is required for translocation. Ball and stick models of ␣-amanitin (red bonds) and of pol II residues within 4 Å (gray bonds) are shown. Rpb1 from A700 to A809 (funnel region) is light green. Rpb1 from A810 to A825 (bridge helix) is dark green. Rpb2 from B760 to B769 is blue. This figure was generated by using BOBSCRIPT and RASTER3D (21) (22) (23) .
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